Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group.
Klintmalm
G B
GB
Baylor University Medical Center, Dallas, Texas.
Goldstein
R
R
Gonwa
T
T
Wiesner
R H
RH
Krom
R A
RA
Shaw
B W
BW
Stratta
R
R
Ascher
N L
NL
Roberts
J W
JW
Lake
J
J
D000206:Actuarial Analysis; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001706:Biopsy; D016572:Cyclosporine / Q000627:therapeutic use*; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology; D016853:Muromonab-CD3 / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D000305:Adrenal Cortex Hormones; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D016559:Tacrolimus